p53 antibody (Tumor Protein P53) (FITC)

Details for Product anti-TP53 Antibody No. ABIN94449
Antigen
Reactivity
Human, Non-Human Primate
2161
483
466
251
91
65
62
33
25
21
19
14
13
7
6
5
4
4
4
4
3
3
3
3
2
1
1
Host
Mouse
1558
667
7
5
1
1
1
Clonality (Clone)
Monoclonal ()
Conjugate
This p53 antibody is conjugated to FITC
84
53
41
40
40
39
39
39
38
25
22
21
12
12
12
12
12
8
7
7
7
7
7
7
7
7
7
7
7
7
7
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
Application
ELISA, Flow Cytometry (FACS), Immunocytochemistry (ICC), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunoprecipitation (IP), Western Blotting (WB)
1712
741
712
526
387
379
281
155
98
84
61
49
41
41
32
28
20
19
15
15
6
3
3
2
2
2
1
1
1
1
1
1
1
1
Options
Immunogen Bacterially expressed full-length wild-type p53
Clone BP53-12
Isotype IgG2a
Specificity The antibody BP53-12 recognizes defined epitope (aa 16-25) on human p53, a 50 kDa tumour suppressor found in increased amounts in a wide variety of transformed cells, it is frequently mutated or inactivated in many types of cancer.
Cross-Reactivity (Details) Human, Non-Human Primates
Antigen
Alternative Name p53 (TP53 Antibody Abstract)
Background The tumour suppressor protein p53 is a key element of intracellular anticancer protection. It mediates cell cycle arrest or apoptosis in response to DNA damage or to starvation for pyrimidine nukleotides. It is up-regulated in response to these stress signals and stimulated to activate transcription of specific genes, resulting in expression of p21waf1 and other proteins involved in G1 or G2/M arrest, or proteins that trigger apoptosis, such as Bcl-2. The structure of p53 comprises N-terminal transactivation domain, central DNA-binding domain, oligomerisation domain, and C-terminal regulatory domain. There are various phosphorylation sites on p53, of which the phosphorylation at Ser15 is important for p53 activation and stabilization.
Pathways p53 Signaling, MAPK Signaling, PI3K-Akt Signaling, Apoptosis, AMPK Signaling, Chromatin Binding, ER-Nucleus Signaling, Positive Regulation of Endopeptidase Activity, Hepatitis C, Protein targeting to Nucleus, Autophagy
Application Notes The reagent is designed for direct immunofluorescence analysis.Note: This conjugate is routinely tested by flow cytometry analysis using permeabilized transient wild-type p53-tranfectants.
Comment

The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under optimum conditions. The reagent is free of unconjugated FITC.

Restrictions For Research Use only
Concentration 1 mg/mL
Buffer Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4
Preservative Sodium azide
Precaution of Use This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice Do not freeze.
Avoid prolonged exposure to light.
Storage 4 °C
Storage Comment Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.
Supplier Images
Image no. 1 for anti-Tumor Protein P53 (TP53) antibody (FITC) (ABIN94449) Confocal microscopy of human HeLa cells using anti-p53 (BP53-12 ; FITC). The expressi...
Product cited in: Dolezalová, Vojt?sek, Kovarík: "Epitope analysis of the human p53 tumour suppressor protein." in: Folia biologica, Vol. 43, Issue 1, pp. 49-51, 1997 (PubMed).

Bártek, Bártková, Vojt?sek, Stasková, Lukás, Rejthar, Kovarík, Midgley, Gannon, Lane: "Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies." in: Oncogene, Vol. 6, Issue 9, pp. 1699-703, 1991 (PubMed).

Bártková, Bártek, Lukás, Vojt?sek, Stasková, Rejthar, Kovarík, Midgley, Lane: "p53 protein alterations in human testicular cancer including pre-invasive intratubular germ-cell neoplasia." in: International journal of cancer. Journal international du cancer, Vol. 49, Issue 2, pp. 196-202, 1991 (PubMed).